Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients

Ronald J Corbee*, Dion L van Everdingen, Hans S Kooistra, Louis C Penning

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Fibroblast growth factors (FGFs) are involved in numerous metabolic processes. The endocrine subfamily of FGFs, consisting of FGF19, FGF21, and FGF23, might have beneficial effects in the treatment of diabetes mellitus (DM) and/or obesity. The analog with the greatest potential, FGF21, lowers blood glucose levels, improves insulin sensitivity, and induces weight loss in several animal models. In this review we summarize recent (pre)clinical findings with FGF21 analogs in animal models and men. Furthermore, possible applications of FGF21 analogs for pets with DM will be discussed. As currently, information about the use of FGF21 analogs in pet animals is scarce.

Original languageEnglish
Article number1086987
Pages (from-to)1-8
Number of pages8
JournalFrontiers in Veterinary Science
Volume9
Early online date2022
DOIs
Publication statusPublished - 9 Jan 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 Corbee, van Everdingen, Kooistra and Penning.

Keywords

  • FGF
  • diabetes
  • endocrine
  • glucose
  • insulin
  • metabolism
  • obesity

Fingerprint

Dive into the research topics of 'Fibroblast growth factor-21 (FGF21) analogs as possible treatment options for diabetes mellitus in veterinary patients'. Together they form a unique fingerprint.

Cite this